**Pyruvinium pamoate**

Cat. No.: HY-A0293  
CAS No.: 3546-41-6  
Molecular Formula: $C_{26}H_{28}N_3\cdot\frac{1}{2}C_{23}H_{14}O_6$  
Molecular Weight: 575.7  
Target: Wnt  
Pathway: Stem Cell/Wnt  
Storage: 4°C, sealed storage, away from moisture and light  

* The compound is unstable in solutions, freshly prepared is recommended.

### SOLVENT & SOLUBILITY

<table>
<thead>
<tr>
<th>In Vitro</th>
<th>DMSO : 17.86 mg/mL (31.02 mM; Need ultrasonic)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Preparation</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Concentration</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Mass</strong></td>
</tr>
<tr>
<td></td>
<td>1 mg</td>
</tr>
<tr>
<td></td>
<td>5 mg</td>
</tr>
<tr>
<td></td>
<td>10 mg</td>
</tr>
<tr>
<td>1 mM</td>
<td>1.7370 mL</td>
</tr>
<tr>
<td>5 mM</td>
<td>0.3474 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td>0.1737 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

**Description**  
Pyruvinium pamoate is an FDA-approved antihelmintic agent that inhibits WNT pathway signaling.

**In Vitro**  
Pyruvinium pamoate (0-500 nM) inhibits proliferation of MCF-7 (luminal), MDA-MB-231 (claudin-low), MDA-MB-468 (basal-like) and SkBr3 (HER2-OE) cells in a dose-dependent manner, with IC$_{50}$ value of 1170±105.0 nM against MDA-MB-231 cell line. Pyruvinium pamoate significantly inhibits self-renewal and proliferation of BCSCs, and suppresses BCSC population with a distinct phenotype. Pyruvinium pamoate significantly decreases average expression levels of FZD1, FZD10, WNT1, WNT7B, CTNNB1, MYC, and LRP5 at transcriptional level. Moreover, Pyruvinium pamoate also efficiently down-regulates the expression of other stemness genes including ALDH1, CD44 and ABCG2$^{[1]}$. Pyruvinium pamoate blocks colon cancer cell growth in vitro in a dose-dependent manner with great differences in the inhibitory concentration (IC$_{50}$), ranging from 0.6 to 65 μM for colon cancer cells with mutations in WNT signaling. Pyruvinium pamoate decreases messenger RNA (mRNA) and protein levels of known WNT target genes as c-MYC and thereby led to the induction of p21$^{[2]}$. Pyruvinium pamoate ultimately inhibits Wnt signalling despite its lack of efficacy on CK1$^{[3]}$. Pyruvinium pamoate imposes specific toxicity on cardiac fibroblasts in ischemia (IC$_{50}$=9.5 nM). The cytotoxic effect of Pyruvinium pamoate on cardiac fibroblasts specifically under glucose- and glutamine-deficient condition$^{[4]}$.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**In Vivo**  
In the xenograft model, Pyruvinium pamoate (500 nM)-pretreatment strongly delays tumor size and tumor weight, and the...
tumor volume is markedly decreased\[1\].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

### Cell Assay \[1\]

Pyrvinium pamoate is dissolved in DMSO at a concentration of 1 μM and is stocked in aliquots at -20°C. Cells (1×10⁴) are suspended in 200 μL culture medium and then seeded into 96-well plates in quintuplicate overnight. Cells are treated with indicated concentrations of Pyrvinium pamoate (0-8,000 μM). After incubating for 3 days, CCK8 (10 μL) is added into each well and incubated at 37°C for 1 h. The absorbance is measured using a microplate reader at 450 nm\[1\].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### Animal Administration \[1\]

Mice: NOD/SCID mice are housed under aseptic conditions in individually ventilated cages. For xenografting, 5×10⁶ Pyrvinium pamoate-pretreated or untreated breast cancer cells (MDA-MB-231) are resuspended in a 1:1 mixture of culture medium and Matrigel and then transplanted into the fourth pair of mammary fat pads of mice (4-6-week-old). After injection, tumor size is measured by calipers each day and tumor growth is plotted. Upon reaching the endpoint, mice are sacrificed and tumors are harvested. All the tumors are formalin-fixed, and paraffin-embedded for hematoxylin and eosin and immunohistochemical staining\[1\].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Transl Oncol. 2021 Mar 2;14(5):101048.
- Endocrinology. 2023 Mar 17;bqad042.
- Methods Appl Fluoresc. 2021 May 27.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES


Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898  Fax: 609-228-5909  E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA